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Background: Several standard venous assessment tools have been used as independent determinants of venous disease
severity, but correlation between these instruments as a global venous screening tool has not been tested. The scope of this
study is to assess the validity of Venous Clinical Severity Scoring (VCSS) and its integration with other venous assessment
tools as a global venous screening instrument.
Methods: The American Venous Forum (AVF), National Venous Screening Program (NVSP) data registry from 2007 to
2009 was queried for participants with complete datasets, including CEAP clinical staging, VCSS, modified Chronic
Venous Insufficiency Quality of Life (CIVIQ) assessment, and venous ultrasound results. Statistical correlation trends
were analyzed using Spearman’s rank coefficient as related to VCSS.
Results: Five thousandeighthundred fourteen limbs in2,907participantswere screenedand includedCEAPclinical stageC0:26%;
C1: 33%; C2: 24%; C3: 9%; C4: 7%; C5: 0.5%; C6: 0.2% (mean, 1.41 1.22). VCSS mean score distribution (range, 0-3) for the
entire cohort included: pain 1.010.80, varicose veins 0.610.84, edema0.610.81, pigmentation0.150.47, inflammation
0.07 0.33, induration 0.04 0.27, ulcer number 0.004 0.081, ulcer size 0.007 0.112, ulcer duration 0.007 0.134, and
compression0.300.81.Overall correlationbetweenCEAPandVCSSwasmoderately strong(rs0.49;P< .0001),withhighest
correlation for attributes reflectingmore advanced disease, including varicose vein (rs0.51;P< .0001), pigmentation (rs0.39;
P< .0001), inflammation (rs 0.28;P< .0001), induration (rs 0.22; P< .0001), and edema (rs 0.21; P< .0001). Based
on themodified CIVIQ assessment, overall mean score for each general category included: Quality of Life (QoL)-Pain 6.04
3.12 (range, 3-15), QoL-Functional 9.90  5.32 (range, 5-25), and QoL-Social 5.41  3.09 (range, 3-15). Overall
correlation between CIVIQ and VCSS was moderately strong (rs 0.43; P< .0001), with the highest correlation noted for
pain (rs 0.55; P< .0001) and edema (rs 0.30; P< .0001). Based on screening venous ultrasound results, 38.1% of limbs
had reflux and 1.5% obstruction in the femoral, saphenous, or popliteal vein segments. Correlation between overall venous
ultrasound findings (reflux obstruction) and VCSSwas slightly positive (rs 0.23; P< .0001) but was highest for varicose
vein (rs 0.32; P< .0001) and showed no correlation to swelling (rs 0.06; P< .0001) and pain (rs 0.003; P .7947).
Conclusions:While there is correlationbetweenVCSS,CEAP,modifiedCIVIQ,andvenousultrasoundfindings, subgroupanalysis
indicates that this correlation is driven by different components of VCSS compared with the other venous assessment tools. This
observation may reflect that VCSS has more global application in determining overall severity of venous disease, while at the same
time highlighting the strengths of the other venous assessment tools. (J Vasc Surg 2011;54:2S-9S.)
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Volume 54, Number 19S Passman et al 3SVenous outcomes assessment tools have been used to
evaluate the severity of venous disease and provide stan-
dardized evaluation of treatment effectiveness. While the
CEAP classification system for chronic venous disease is
useful to classify stages of venous disease, enabling patient
comparison among different centers and studies, its com-
ponents have been recognized to be relatively static and
insufficient for determining changes in venous disease se-
verity.1,2 In an effort to improve standardized outcome
assessment of venous disease with gradable elements that
can change in response to treatment, in 2000, the American
Venous Forum (AVF), Ad Hoc Committee on Venous
Outcomes Assessment, proposed the Venous Clinical Se-
verity Score (VCSS).3 The VCSS system includes 10 clinical
descriptors (pain, varicose veins, venous edema, skin pig-
mentation, inflammation, induration, number of active
ulcers, duration of active ulceration, size of ulcer, and
compressive therapy use), scored from 0 to 3 (total possible
score, 30) that may be used to assess changes in response to
therapy. While VCSS has been shown to have minimal
intraobserver and interobserver variability,4 validation with
objective venous parameters has been reserved to only a few
studies with limited sample size.5,6 Despite lack of ex-
tended validation, there has been general acceptance and
wide dissemination of VCSS for clinical and research pur-
poses.7-14
With the creation of the AVF, the National Venous
Screening Program (NVSP) in 2005, and its expansion in
2007,15,16 several standard venous assessment tools were
incorporated into the screening process as independent
determinants of venous disease severity, but correlation
between these instruments as a global venous screening
tool has not been tested. The scope of this study is to assess
the validity of VCSS and its integration with other venous
assessment tools as a global venous screening instrument.
METHODS
Screening program. Since its inception in 2005, the
AVF NVSP has had the mission of increasing awareness of
acute and chronic venous disease through education on
venous thromboembolism (VTE) and chronic venous in-
sufficiency; identification of those at risk for VTE, the
presence of venous obstruction or reflux, and the presence
of chronic venous insufficiency; and empowerment of par-
ticipants to inform others about the risk or presence of
venous disease. Oversight of the NVSP is provided by the
NVSP committee of the AVF (chairman, M.P.) under the
direction of the AVF Executive Committee and leadership,
NVSP administrative coordinator (M.L., RF Associates,
Baltimore, MD), and Administrare, Inc. (Salem, MA).
Nationwide site recruitment and participation in the NVSP
during the study period was sought through medical soci-
eties interested in venous disease: the AVF, the Society for
Vascular Surgery, and the American College of Phlebology.
A training NVSP toolkit and all related screening and
educational material was provided to interested sites
through unrestricted educational grants from Juzo Cor- ioration (Cleveland, OH) and Sanofi-Aventis (Bridge-
ater, NJ).
The NVSP screening process has been described and
alidated elsewhere.15,16 Briefly, participants completed a
elf-administered demographic questionnaire and VTE risk
ssessment,17 underwent a focused lower extremity exam-
nation, and were graded according to CEAP classifica-
ion.1,2 In 2007, VCSS3 and abbreviated Chronic Venous
nsufficiency Quality of Life (CIVIQ)18,19 assessments
ere added to the screening process. An abbreviated ve-
ous duplex ultrasound examination for venous reflux and
bstruction by vascular technicians at each site was per-
ormed on all participants. Venous duplex ultrasound
creening focused on common femoral vein, saphenofemo-
al junction, and above-knee popliteal venous segments.
ith participants in the supine position and the head of the
ed elevated to 30 degrees, a Valsalva maneuver was per-
ormed at each vein location with manual compression
sing B-mode to evaluate for obstruction, defined as inabil-
ty to completely oppose vein walls, or reflux, defined as
eversal of flow 0.5 seconds. An exit interview with the
articipant was performed by a health care provider at each
ite to review the venous screening findings. Participants
eceived free venous disease educational brochures and a
enous report card with direction to share the report with
heir primary care provider. All screening sites were re-
uested to return collected data points without participant
dentifiers to NVSP administrative coordinator (M.L.) with
ata entry into the NSVP quality assurance registry (Access;
icrosoft Corp., Seattle, WA).
Study design. The NVSP registry was queried for all
articipants with complete screening datasets from 2007 to
009 for inclusion in the analysis. Inclusion in the study
equired complete participant data sets, including collected
emographic data, clinical information, VTE risk assess-
ent, CEAP, VCSS, abbreviated CIVIQ, and venous ul-
rasound findings. The VTE risk assessment, modified from
TE risk scoring system reported by Caprini et al,17 eval-
ated participants’ risk of developing VTE if placed into a
igh-risk situation (such as surgical procedure, major injury
r other hospitalizations, malignancy, or prolonged immo-
ility). Point scores based on the severity of individual VTE
isk factors were assigned and totaled for a final VTE risk
core and then categorized as low risk (0-1 point), moder-
te risk (2 points), high risk (3-4 points), and very high risk
5 points). Clinical CEAP classification was determined
y direct physical inspection of lower extremities by provid-
rs at each site (C0: No visible or palpable signs of venous
isease; C1: Telangiectasies or reticular veins; C2: Varicose
eins; C3: Edema; C4: Changes in skin and subcutaneous
issue; C5: Healed venous ulcer; C6: Active venous ul-
er).1,2 VCSS was determined based on current published
eporting standards with scores for each attribute (0-3
oints) and total score determined (Table I), from data
ollected on subjective questionnaire and direct physical
ssessment provider on site.3 The abbreviated CIVIQ ques-
ionnaire ranked symptoms experienced during the preced-
ng 4 weeks prior to screening according to a Likert scale of
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December Supplement 20114S Passman et al1 to 5 (1 - no pain/not bothered at all; 5 - intense
pain/impossible to do). For data analysis, the 11 questions
used in abbreviated CIVIQ were categorized as follows:
pain (four questions), physical functioning (four ques-
tions), and social activities (three questions). Venous ultra-
sound findings of reflux or obstruction in the common
femoral vein, saphenofemoral junction, or popliteal vein
were stratified for descriptive purposes, but were combined
either as presence or absence in the statistical analysis.
Statistics. Statistical analyses were performed using
SAS v9.1 (SAS Institute Inc., Cary, NC) with statistical
assistance provided through the Division of Vascular Sur-
gery and Endovascular Therapy, Department of Surgery,
University of Alabama at Birmingham (S.N.). Analysis was
separated as participant or limb based when appropriate.
Descriptive statistics were used for VTE risk factors, CEAP
classification, VCSS, CIVIQ, and presence/absence of ve-
nous reflux and obstruction. Correlation trends as related
to VCSS were determined using Spearman’s rank coeffi-
cient (ordinal variables, nonparametric). When testing
VCSS score for each limb against other limb based tests
(CEAP, venous ultrasound), analysis was based on each
limb. When testing VCSS against participant-based tests
(VTE risk score, CIVIQ) analysis was performed both
based on total number of limbs versus participants and
based on random sampling of one limb per participant.
Correlation was rated as follows: Very Weak/Negligible:
rs 0.0 to 0.2; Weak/Low: rs 0.2 to 0.4; Moderate: rs
0.4 to 0.7; Strong/High: rs 0.7 to 0.9; Very Strong: rs
0.9 to 1.0.
RESULTS
Over the 2-year period, complete data sets were avail-
able for analysis on 5,814 limbs screened in 2,907 partici-
pants. Mean age was 58.9  13.3 years, with a gender
distribution of female (n 2180; 75%) and male (n 727;
25%). Mean body mass index was 29.2  7.3. Race distri-
bution included Caucasian (n  2326; 80%), African-
American (n  233; 8%), Hispanic (n  87; 3%), Asian
(n  84; 3%), and other (n  177; 6%). Pre-existing
medical factors included: hypertension (n  988; 34%);
diabetes mellitus (n  291; 10%); congestive heart failure
Table I. Venous Clinical Severity Scoring system used by
Attribute Absent (0) Mild
Pain None Occasio
Varicose veins None Few
Venous edema None Evening
Skin pigmentation None Limited
Inflammation None Mild cel
Induration None Focal 
No. of active ulcers None 1
Active ulcer size None 2 cm
Ulcer duration None 3 mon
Compression None Intermit
NVSP, National Venous Screening Program.(n  57; 2%); tobacco history: nonsmoker (n  1742; f0%), past smoker (n  960; 33%), current smoker (n 
05; 7%); and pertinent medications: aspirin (n  638;
2%), clopidogrel (n  57; 2%), other antiplatelet medica-
ion (n  30; 1%), and warfarin (n  118; 4%).
Mean total VCSS score (n  5814 limbs) was 2.83 
.47. VCSS mean score distribution for each category
range, 0-3) was pain 1.01  0.80; varicose veins 0.61 
.84; edema 0.61  0.81; pigmentation 0.15  0.47;
nflammation 0.07  0.33; induration 0.04  0.27; ulcer
umber 0.004  0.081; ulcer size 0.007  0.112; ulcer
uration 0.007  0.134; and compression 0.30  0.81.
Mean clinical CEAP clinical classification (n  5814
imbs) was 1.4  1.2, with CEAP clinical classification
istribution: C0: 26%; C1: 33%; C2: 24%; C3: 9%; C4: 7%;
5: 0.5%; and C6: 0.2%. Overall correlation between
EAP and VCSS was moderate (rs  0.49; P  .0001),
ith highest correlation for VCSS attributes reflecting
ore advanced disease, including varicose vein (rs  0.51;
 .0001) and pigmentation (rs  0.39; P  .0001); low
orrelation for inflammation (rs 0.28; P .0001), indu-
ation (rs  0.22; P  .0001), and edema (rs  0.21; P 
0001; Table II).
VTE risk assessment scoring for each participant ques-
ion (n  2907; Table III) is noted for prior deep vein
hrombosis/pulmonary embolism (DVT/PE) in 7.9% and
P
Moderate (2) Severe (3)
Daily Daily with meds
Multiple Extensive
Afternoon Morning
Diffuse, more recent Wider, recent
Moderate cellulitis Severe
1/3 gaiter 1/3 gaiter
2 2
2-6 cm 6 cm
3-12 months 1 year
Most days Fully compliant
able II. Correlation between VCSS parameters and
ean clinical CEAP score (n  5814 limbs)
CSS CEAP score (rs)
ain 0.12 (P  .0001)
aricose vein 0.51 (P  .0001)
dema 0.21 (P  .0001)
igmentation 0.38 (P  .0001)
nflammation 0.27 (P  .0001)
nduration 0.21 (P  .0001)
lcer number 0.07 (P  .0001)
lcer size 0.05 (P  .0001)
lcer duration 0.08 (P  .0001)
ompression 0.18 (P  .0001)
CSS, Venous Clinical Severity Score.
pearman correlation: medium gray  moderate correlation; light gray 
eak/low correlation; white  very weak/negligible correlation.NVS
(1)
nal
only
, old
lulitis
5 cm
ths
tentamily history of DVT/PE in 19.1%. Mean total VTE risk
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Volume 54, Number 19S Passman et al 5Sscore was 3.8 2.2. VTE risk assessment score distribution
for participants (anticipated risk estimate if placed in a
high-risk situation for DVT/PE) was Low Risk (0-1 point)
11%;Moderate Risk (2 points) 21%; High Risk (3-4 points)
35%; Very High Risk (5 points) 33% (Fig). Overall cor-
relation between VTE risk assessment and VCSS for all
limbs was low (rs 0.34; P .0001) with weak/negligible
correlation for most VCSS parameters (Table IV). There
was no difference noted in correlation tables between VCSS
and VTE risk assessment score comparing VCSS for all
limbs and random sampling of VCSS based on one limb per
participant.
Based on the modified CIVIQ assessment, overall
mean score for each participant (n  2907) as per general
category included: Quality of Life (QoL)-Pain 6.04 3.12
(range, 3-15), QoL-Functional 9.90 5.32 (range, 5-25),
and QoL-Social 5.41  3.09 (range, 3-15). Overall corre-
lation between CIVIQ and VCSS for all limbs was moder-
ately strong (rs  0.43; P  .0001), with highest correla-
tion noted for pain (r  0.55; P .0001) and edema (r 
Table III. VTE risk assessment profile based on
subjective questionnaire and point scoring system for
participants undergoing venous screening (n  2907)
VTE Risk Assessment Questions Points N (%)
1. Have you ever had a blood clot in
your legs or lungs?
3 230 (7.9%)
2. Do you have a family history of blood
clots in the veins?
3 558 (19.1%)
3. Do you currently or have you ever
had swollen legs?
1 716 (24.6%)
4. Do you have visible varicose veins
other than spider veins?
1 2139 (73.6%)
5. Do you have ileitis, Crohn’s disease,
or inflammatory bowel disease?
1 176 (6.1%)
6. Do you have serious lung disease or
emphysema?
1 113 (3.9%)
7. Within the last month, have you had
more than 3 days of continuous bed
rest attributable to injury or illness?
1 85 (2.9%)
8. Within the last month, have you had a
pelvic fracture or a plaster leg cast?
1 17 (0.6%)
9. Have you had a stroke, heart attack,
or heart failure?
1 201 (6.9%)
10. Have you had major surgery lasting
over an hour in the last month?
1 32 (1.1%)
11. Do you have or have you had a ma-
lignant disease (cancer)?
1 293 (10.1%)
12. Do you weigh over 250 pounds? 1 164 (5.6%)
13. Age between 40-59 years? 1 1241 (42.7%)
14. Age between 60-69 years? 2 752 (25.9%)
15. Age equal to or greater than 70
years?
3 649 (22.3%)
Women only
16. Do you take birth control pills or
estrogen (hormone) replacement
therapy?
1 252 (8.7%)
17. Are you pregnant or have you given
birth within the last month?
1 14 (0.5%)
VTE, Venous thromboembolism.s s
0.30; P  .0001; Table V). There was no difference noted Wn correlation tables between VCSS and CIVIQ comparing
CSS for all limbs and random sampling of VCSS based on
ne limb per participant.
Based on screening venous ultrasound results, 38.1% of
imbs had Reflux and 1.5%Obstruction in at least one of the
egments imaged. Distribution of venous ultrasound re-
ults for all segments showed: Reflux – 18.6% femoral,
8.6% saphenous, 9.3% popliteal vein; Obstruction 0.4%
emoral, 0.4% saphenous, 0.6% popliteal. Correlation be-
ween overall venous ultrasound findings (Reflux  Ob-
truction) and VCSS was low (rs  0.23; P  .0001) but
as highest for varicose vein (rs  0.32; P  .0001;
able VI).
ISCUSSION
Methods for reporting venous outcomes have been in
xistence for many years, with more recent emphasis on
hysician-generated assessment tools that can be used to
ollow clinically defined end points and changes over time.
ig. VTE risk assessment score distribution (y axis) for NVSP
articipants (x axis; n  2907).
able IV. Correlation between VCSS parameters (n 
814 limbs) and mean total VTE risk assessment score
n  2907 participants)
CSS VTE Risk Assessment (rs)
ain 0.17 (P  .0001)
aricose vein 0.20 (P  .0001)
dema 0.24 (P  .0001)
igmentation 0.18 (P  .0001)
nflammation 0.13 (P  .0001)
nduration 0.11 (P  .0001)
lcer number 0.04 (P  .0001)
lcer size 0.04 (P  .0001)
lcer duration 0.03 (P  .0001)
ompression 0.18 (P  .0001)
CSS, Venous clinical severity score; VTE, venous thromboembolism.
pearman correlation: light gray  weak/low correlation; white  very
eak/negligible correlation.hile several venous outcome assessment tools exist, there
v
t
n
w
f
t
f
c
c
d
t
V
V
V
r
s
.
p
a
o
w
v
s
v
e
i
c
v
t
a
i
a
n
V
p
d
e
i
s
eak/l
JOURNAL OF VASCULAR SURGERY
December Supplement 20116S Passman et alis no universally accepted system. In part, this reflects
different emphasis within each scoring system from rela-
tively static elements in clinical CEAP; to subjective param-
eters in venous quality-of-life disease-specific instruments
such as CIVIQ used in this study or others such as the
Venous Insufficiency Epidemiological and Economic
Study,20 the Aberdeen Varicose Vein Questionnaire,21,22
and the Charing Cross Venous Ulceration Question-
naire;23 to serial venous severity assessment tools such as
Venous Severity Scoring (VSS), which includes Venous
Disability Score (VDS), Venous Segmental Disease Score
(VSDS), and VCSS.3 Use of venous disease severity scoring
should allow patient groups with similar degrees of severity
to be compared in regard to outcome over time and fol-
lowing different therapies. Of the different venous severity
assessment tools available, VCSS has been shown to parallel
the severity of venous disease reliably and is the focus of this
study.
While there has been general acceptance and wide
dissemination of VCSS for clinical and research pur-
poses, validation has been limited to only a few studies.
Meissner et al,4 in a validation study of VCSS involving
Table V. Correlation between VCSS parameters (n  581
Functional, and QoL-Social (n  2901 participants)
VCSS Total CIVIQ score (rs) QoL – P
Pain 0.55 (P  .0001) 0.58 (P
Varicose vein 0.09 (P  .0001) 0.07 (P
Edema 0.30 (P  .0001) 0.25 (P
Pigmentation 0.06 (P  .0001) 0.04 (P
Inflammation 0.06 (P  .0001) 0.04 (P
Induration 0.06 (P  .0001) 0.04 (P
Ulcer number 0.02 (P  .0001) 0.03 (P
Ulcer size 0.02 (P  .0001) 0.04 (P
Ulcer duration 0.007 (P  .0001) 0.0016 (P
Compression 0.14 (P  .0001) 0.12 (P
CIVIQ, Chronic Venous Insufficiency Quality of Life; QoL, quality of life; V
Spearman correlation: medium gray  moderate correlation; light gray  w
Table VI. Correlation between VCSS parameters and
positive venous ultrasound results (reflux  obstruction;
n  5814 limbs)
VCSS Venous ultrasound finding (rs)
Pain 0.03 (P  .7947)
Varicose vein 0.31 (P  .0001)
Edema 0.06 (P  .0001)
Pigmentation 0.19 (P  .0001)
Inflammation 0.16 (P  .0001)
Induration 0.10 (P  .0001)
Ulcer number 0.05 (P  .0001)
Ulcer size 0.05 (P  .0011)
Ulcer duration 0.04 (P  .0004)
Compression 0.12 (P  .0001)
VCSS, Venous Clinical Severity Score.
Spearman correlation: light gray  weak/low correlation; white  very
weak/negligible correlation.128 limbs in 64 consecutive patients with known chronic tenous disease that were scored by separate observers at
ime zero and again within 28 days, found that there was
o significant difference in intraobserver variability, and
hile interobserver reliability was good, there were dif-
erences noted in interobserver pain scores, skin pigmen-
ation, and inflammation, leading to recommendation
or refinements of the VCSS for better reliability in these
ategories. Gillet et al,7 in 2894 patients with ultrasound
onfirmed chronic venous insufficiency involving the
eep venous system, used CEAP classification to assess
he severity of venous disease and correlate with VCSS,
SDS, and VDS. A significant increase in VCSS and
SDS (P  .0001) paralleled CEAP clinical class, with
DS higher in the C3 and C6 classes although not
eaching significance because of small sample size, a
ignificant link between the pain in VCSS and VDS (P 
0001), and significant increase in VCSS according to the
resence of incompetent perforator vein (P  .05)
nd/or reflux in the deep femoral vein (P  .05). In an
bservational study, including 45 patients who under-
ent superficial venous surgery in 48 legs with primary
aricose veins, Kakkos et al6 showed that venous severity
cores were significantly higher in limbs with advanced
enous disease, demonstrating correlation with anatomic
xtent and that VCSS was better for measuring changes
n response to superficial venous surgery than CEAP
linical class, leading to the conclusion that venous se-
erity scoring systems should be used in clinical studies
o quantify venous outcome. Ricci et al5 evaluated VCSS
gainst abnormalities found on venous ultrasound scans
n a large kindred cohort of 210 patients with hyperco-
gulable state. VCSS showed good association with ve-
ous ultrasound abnormalities. Interestingly, when
CSS was zero, there was a high likelihood that the
atient did not have venous disease. Although VCSS was
evised to quantify the severity of chronic venous dis-
ase, evidence supported VCSS as a useful venous screen-
ng tool. While the use of the VCSS as an independent
creening instrument was suggested, additional valida-
bs) and mean total CIVIQ score, QoL-Pain, QoL-
rs) QoL – Functional (rs) QoL – Social (rs)
001) 0.50 (P  .0001) 0.42 (P  .0001)
001) 0.08 (P  .0001) 0.07 (P  .0001)
001) 0.29 (P  .0001) 0.24 (P  .0001)
001) 0.06 (P  .0001) 0.05 (P  .0001)
001) 0.06 (P  .0001) 0.06 (P  .0001)
001) 0.06 (P  .0001) 0.04 (P  .0001)
001) 0.014 (P  .0001) 0.002 (P  .0001)
001) 0.002 (P  .0001) 0.004 (P  .0001)
001) 0.004 (P  .0001) 0.006 (P  .0001)
001) 0.13 (P  .0001) 0.13 (P  .0001)
Venous Clinical Severity Score.
ow correlation; white  very weak/negligible correlation.4 lim
ain (
 .0
 .0
 .0
 .0
 .0
 .0
 .0
 .0
 .0
 .0
CSS,ion would be required.
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Volume 54, Number 19S Passman et al 7SWhile the validity of VCSS independently or in con-
junction with other venous severity assessment tools has
been supported by several other studies, integration of
VCSS with other venous assessment tools as a global
venous screening instrument has not been widely tested.
The AVF, NVSP data set offers a large population sample
of participants screened for venous disease using these
various venous severity assessment tools. Several stan-
dard venous assessment tools, including VTE risk assess-
ment, CEAP, clinical examination, and venous ultra-
sound were incorporated initially into NVSP in 2005,
with expanded parameters in 2007, including VCSS and
CIVIQ. With a large data set accrued over 2 years of
5814 limbs in 2907 screened participants, there is a
unique opportunity to compare venous outcome assess-
ment parameters for correlation with VCSS. Similar to
several of the studies cited above, there was overall
parallel correlation between VCSS and clinical CEAP
(moderate; rs  0.49; P  .0001) in this study. Much of
this correlation with clinical CEAP was driven by attri-
butes reflecting more advanced disease, including vari-
cose vein (rs  0.51; P  .0001) and pigmentation (rs 
0.39; P  .0001) and lesser correlation with inflamma-
tion (rs  0.28; P  .0001), induration (rs  0.22; P 
.0001), and edema (rs  0.21; P  .0001). Given that
these areas of correlation represent overlapping aspects
of both VCSS and clinical CEAP, some relationship
between severity as reflected in each scoring system is
predictable. While correlation between VCSS and clini-
cal CEAP was overall moderate, any disparity may be
more reflective of the difference between clinical CEAP,
which is dependent on consecutive ordinal variables of
increasing severity, and VCSS, which stratifies severity of
each attribute and may be more accurate in determining
severity distribution. Similarly, this overlapping trend
may also explain the observed overall moderately strong
correlation between VCSS and modified CIVIQ (rs 
0.43; P .0001), with highest correlation noted for pain
(rs  0.55; P  .0001) and edema (rs  0.30; P 
.0001), both of which are well represented in both VCSS
and modified CIVIQ.
In contrast to Ricci et al,5 in this study, correlation
between overall venous ultrasound findings and VCSS was
low (rs  0.23; P  .0001) and again was highest for
varicose vein (rs 0.32; P .0001). Much of this disparity
may reflect differences in venous ultrasound screening tech-
niques used in this study compared with other more com-
prehensive ultrasound used in other studies. Venous ultra-
sound used in NVSP was intended to be a rapid screening
technique focusing on identification of obvious obstruction
or reflux in just three locations: common femoral vein,
saphenofemoral junction, and above-knee popliteal venous
segments. While venous duplex ultrasound examination
used in NVSP had been previously validated as a screening
tool,15,16 as an objective screening parameter performed in
a just few minutes directed at identifying obvious disease in
most common locations with provocative maneuvers lim-
ited to Valsalva only, there may be missed venous reflux or Vbstruction that would have otherwise been detected on a
ore comprehensive ultrasound examination.
While there is general overall correlation between
CSS and the other venous parameters used in NVSP
hat trends parallel to severity of venous disease, the
trength of this correlation may be influenced by factors
eflective of the screening process and variability among
ites. Although the NVSP standardizes the screening
pproach with the infrastructure of the program, forms,
nd educational material provided to each site in the
VSP tool kit, there may still be variability in implemen-
ation of the program between sites. While guidelines are
rovided to each site on how to perform screening
valuation, for the subjective components collected from
articipants, there may be some differences in under-
tanding the questions asked on the demographic ques-
ionnaire; for the objective components collected by
ach site’s providers, there may be variable understand-
ng of the venous physical examination findings; for
bjective venous ultrasound testing, although precise
nstructions are provided to each site on the focused
creening venous ultrasound technique used in NVSP,
here may be differences in interpretation of venous
ltrasound testing at each site. While there may have
een some variability within the individual sites in the
ample used for this dataset, these sites were self-selected
o participate in NVSP and are not a random represen-
ation of all vascular surgery practices. Clinicians at these
ites who volunteered to participate may have a higher
evel of venous disease expertise and pre-existing comfort
ith venous screening instruments. Furthermore, inclu-
ion of only participants with complete datasets for anal-
sis in this study may also reflect sites that followed the
creening protocols more closely, thereby providing bet-
er quality of data with less variance for analysis than
hose sites providing incomplete datasets. Because valid-
ty and reliability are both confounded in this study, the
ifferent correlations between VCSS scores and various
ther measures may be difficult to interpret since some
ay have higher and others may have lower reliability
ndexes. Statistically, this may mean the actual validity of
CSS is higher than stated here or, in contrast because of
higher correlation bias than may have been present in a
ore random sampling, it may actually represent an
pper limit on estimate of correlation. However, the
roblem also remains that there could be correlations of
ero within each treatment site, but because treatment
ites differ on mean scores, the VCSS, CEAP, and CIVIQ
cores would appear to be correlated when examined
cross sites.
Variability in strength of correlation seen in this
tudy between VCSS and other venous outcome assess-
ent tools may also be statistically affected by differences
n the emphasis of the individual venous scoring instru-
ents used in NVSP. While clinical CEAP is a tool for
ategorizing severity of lower limb venous disease based
n objective clinical findings at a single point in time,
CSS was designed to assess changes in venous disease
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mined by the patient and assessed by the provider.
Similarly, VTE risk scoring and CIVIQ incorporate some
variable subjective and objective assessment, while ve-
nous ultrasound is solely an objective focused screening
test. With variable scaling of subjective and objective
interpretation built into each scoring system, there may
be variable penetration into the observed results thereby
affecting degree of correlation.
In addition, VCSS is a limb-based scoring system, and
while some participants may have the same VCSS score for
both limbs, others may have different scores for each limb.
While this is less of a factor when comparing VCSS with
other limb-based tests (ie, CEAP and venous ultrasound),
it can be problematic when analyzing tests based on partic-
ipant factors (ie, VTE risk assessment and CIVIQ), espe-
cially when there is a difference between limbs and it is
not known which limb drives the participant-based
score. Although one would assume that the worse leg has
more impact than the better leg on the participant-based
scores (CIVIQ and VTE risk assessment), these tests do
not differentiate which limb is driving the patient-based
score. Analysis was performed in this study both combin-
ing all limb VCSS scores and as a random single-limb
sampling. Although only the combined results are re-
ported, there was essentially no difference noted in cor-
relation tables between VCSS and VTE risk assessment/
CIVIQ scores comparing the combined-limb analysis
and random sampling of VCSS based on one limb per
participant. Based on the assumptions noted above, the
validity of the statistical analysis performed is qualified
and can be interpreted appropriately in the context of the
observed trends. While VCSS has been recognized to be
a valid outcomes assessment tool, which is further sup-
ported by this study applying VCSS with other venous
outcome systems as a global screening instrument, there
are some shortcomings within VCSS that make universal
applicability difficult and may limit its use as a global
screening instrument. Recommended revisions of VCSS
have focused on simplifying some of the confusing ele-
ments within VCSS while maintaining sensitivity in strat-
ifying the spectrum of venous disease.4,6 With recent
AVF update of VCSS, the goal is keeping core structure
of the current version of VCSS intact, but refining nec-
essary elements to enhance the ability of the VCSS to be
used as an evidence-based outcome measure while allow-
ing ongoing clinical trials using the VCSS to continue
with only minor adjustments.24,25 Based on the obser-
vations in this study, future planned validation of revised
VCSS should factor in the correlation of VCSS with
other venous assessment tools both for trained providers
and for more general applicability as a global venous
screening instrument.
The intention of this study was not to prove the validity
of VCSS as an independent tool, but to show that it works
in conjunction with the other venous outcome tools as part
of the global screening instrument used in AVF-NVSP.
Despite some variability in the NVSP screening data set,verall VCSS still correlated reasonably well with the other
enous scoring systems used in NVSP. While there is cor-
elation in NVSP between VCSS, CEAP, modified CIVIQ
nd venous ultrasound findings, subgroup analysis indi-
ates that this correlation is driven by different components
f VCSS compared with the other venous assessment tools.
his observation may reflect that VCSS has more global
pplication in determining overall severity of venous dis-
ase, while at the same time highlighting the overlapping
trengths of the other venous assessment tools. In conclu-
ion, this study supports the validity of VCSS and its
ntegration with other venous assessment tools as a global
enous screening instrument.
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